Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | CASP2 | P42575 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3831348 | 0.81 | ALDH1A1 (0.42) | NAAAFAAHMEN1KMT2AALDH1A1 | |
| SCHEMBL15708344 | 0.81 | PTPN1 (0.51) | GPR84PTPN1FAAHALDH1A1CNR1 | |
| SCHEMBL13475438 | 0.79 | MCL1 (0.45) | NAAAMCL1MEN1KMT2AALDH1A1 | |
| SCHEMBL2796329 | 0.79 | GPR84 (0.59) | GPR84NAAAFAAHEPHX1CASP2 | |
| SCHEMBL22693798 | 0.76 | ALDH1A1 (0.45) | PTPN1NAAAMEN1KMT2AALDH1A1 | |
| SCHEMBL22693786 | 0.75 | ALDH1A1 (0.46) | PTPN1FAAHMEN1KMT2AALDH1A1 | |
| SCHEMBL3832638 | 0.73 | ALDH1A1 (0.45) | NAAAFAAHMEN1KMT2AALDH1A1 | |
| SCHEMBL23723108 | 0.73 | GPR84 (0.61) | GPR84FAAH | |
| SCHEMBL1982495 | 0.73 | ALDH1A1 (0.50) | GPR84MCL1FAAHMEN1KMT2A | |
| SCHEMBL9432120 | 0.72 | NAAA (0.59) | NAAAFAAHMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6437016-B2 | OMEGA-HYDROXY-N-(ALKYL-OMEGA-ACRYLOYLOXY) ALKYLAMIDES; HIGH RATE OF POLYMERIZATION; COATINGS; INKS; ADHESIVES; OPTICAL, CHEMICAL AND MECHANICAL PROPERTIES; ACRYLATED POLYMERS | DSM N.V. (NL) | 2002-08-20 | — | — | US | disclosed |
| US-20010020050-A1 | Radiation-curable compound | DSM N.V. (NL) | 2001-09-06 | — | — | US | disclosed |
| WO-2000001664-A1 | RADIATION-CURABLE COMPOUND | DSM N.V. (NL) | 2000-01-13 | — | — | WO | disclosed |
| EP-0970945-A1 | Radiation curable acrylic-acid esters containing hydroxyalkylamide groups | DSM N.V. (NL) | 2000-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020050-A1 | Radiation-curable compound | RAD51, ERCC1, XRCC6 | GPR84 1323/4885PTPN1 4873/4885NAAA 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.